Document is current
Any future updates will be listed below
-
Authors
Juliani, Juliani
Tran, Sharon
Harris, Tiffany J.
Ellis, Sarah L. https://orcid.org/0000-0002-5772-6051
Al-Ani, Aysha H.
Wijebandara, Yashodha
Patel, Komal M.
Young, Samuel N. https://orcid.org/0009-0001-6543-1851
Evangelista, Marco
Baloyan, David
Reehorst, Camilla M.
Nightingale, Rebecca
Jenkins, Laura J.
De Cruz, Peter
Duszyc, Kinga
Kile, Benjamin T.
Yap, Alpha S.
Mariadason, John M. https://orcid.org/0000-0001-9123-7684
Christensen, Britt
Samson, André L. https://orcid.org/0000-0002-0637-2716
Murphy, James M. https://orcid.org/0000-0003-0195-3949
Fairlie, Walter D. https://orcid.org/0000-0002-2498-1160
Lee, Erinna F. https://orcid.org/0000-0003-1255-9808
-
Funding
Funding for this research was provided by:
Department of Education and Training | Australian Research Council (DP190102612)
Department of Education and Training | Australian Research Council (DP190102612)
Department of Education and Training | Australian Research Council (DP190102612)
Victorian Cancer Agency (MCRF19045)
La Trobe University
Crohn's and Colitis Australia
Gastroenterological Society of Australia
Department of Health | National Health and Medical Research Council (2008909)
Department of Health | National Health and Medical Research Council (2010704, 1136592)
Department of Health | National Health and Medical Research Council (2002965, 2011584)
Department of Health | National Health and Medical Research Council (1172929, 2034104)
U.S. Department of Defense (HT94252310088)
Kenneth Rainin Foundation
- License Information
-
More Information
Article History
Received: 3 November 2025
Revised: 11 May 2026
Accepted: 5 June 2026
First Online: 17 June 2026
Competing interests
: JMM, ALS, KMP, and SNY contribute to, or have contributed to, the development of necroptosis pathway inhibitors in collaboration with Anaxis Pharma Pty. Ltd. JMM has also received research funding from Anaxis Pharma Pty. Ltd. All other authors declare no competing interests.
